Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Fujita, Shiro ^a   Masago, Katsuhiro ^b   Hatachi, Yukimasa ^b   Fukuhara, Akiko ^b   Hata, Akito ^a   Kaji, Reiko ^a   Kim, Young H ^b   Mio, Tadashi ^b   Mishima, Michiaki ^b   Katakami, Nobuyuki ^a  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PACLITAXEL; TUMOR MARKER; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; NOS3 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; EXON; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTRON; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT; FOLLOW UP; GENETICS; LUNG TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRONS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; NEOPLASM STAGING; NITRIC OXIDE SYNTHASE TYPE III; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78649452865     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-167     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353. 10.1200/JCO.2004.09.053, 14691125.
3. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006, 17:668-675. 10.1093/annonc/mdj135, 16407418.
4. Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006, 6:323-331. 10.1016/j.coph.2006.01.011, 16765644.
5. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 2007, 67:1407-1410. 10.1158/0008-5472.CAN-06-2149, 17308075.
6. Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002, 20:2023-2027. 10.1097/00004872-200210000-00022, 12359981.
7. Tsukada T, Yokoyama K, Arai T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T, Igari J. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998, 245:190-193. 10.1006/bbrc.1998.8267, 9535806.
8. Wang XL, Mahaney MC, Sim AS, Wang J, Blangero J, Almasy L, Badenhop RB, Wilcken DE. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol 1997, 17:3147-3153.
9. Zhang MX, Zhang C, Shen YH, Wang J, Li XN, Chen L, Zhang Y, Coselli JS, Wang XL. Effect of 27nt small RNA on endothelial nitric-oxide synthase expression. Mol Biol Cell 2008, 19:3997-4005. 10.1091/mbc.E07-11-1186, 2526692, 18614799.
10. Zhang MX, Zhang C, Shen YH, Wang J, Li XN, Zhang Y, Coselli J, Wang XL. Biogenesis of short intronic repeat 27-nucleotide small RNA from endothelial nitric-oxide synthase gene. J Biol Chem 2008, 283:14685-14693. 10.1074/jbc.M801933200, 2386909, 18390539.
11. Senthil D, Raveendran M, Shen YH, Utama B, Dudley D, Wang J, Wang XL. Genotype-dependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells. DNA Cell Biol 2005, 24:218-224. 10.1089/dna.2005.24.218, 1350115, 15812238.
12. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717. 10.1378/chest.111.6.1710, 9187198.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, 10.1093/jnci/92.3.205, 10655437.
14. Miyahara K, Kawamoto T, Sase K, Yui Y, Toda K, Yang LX, Hattori R, Aoyama T, Yamamoto Y, Doi Y, Ogoshi S, Hashimoto K, Kawai C, Sasayama S, Shizuta Y. Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. Eur J Biochem 1994, 223:719-726. 10.1111/j.1432-1033.1994.tb19045.x, 7519987.
15. Akaike H. Information Theory and Extension of the Maximam Likelifood Principle. Second International Symposium on Information Theory 1973, 267-281. Budapest: Akademiai Kiadó, Petrov BN, Czáki F.
16. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004, 96:434-442. 10.1093/jnci/djh075, 15026468.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265. 10.1093/bioinformatics/bth457, 15297300.
18. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004, 10:143-145. 10.1016/j.molmed.2004.02.001, 15162796.
19. Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature 2008, 452:646-649. 10.1038/nature06778, 2688829, 18344980.
20. Leung EL, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Br J Cancer 2008, 98:1803-1809. 10.1038/sj.bjc.6604375, 2410127, 18506185.
21. Sonveaux P, Jordan BF, Gallez B, Feron O. Nitric oxide delivery to cancer: why and how?. Eur J Cancer 2009, 45:1352-1369. 10.1016/j.ejca.2008.12.018, 19153039.
22. Reiter CD, Teng RJ, Beckman JS. Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J Biol Chem 2000, 275:32460-32466. 10.1074/jbc.M910433199, 10906340.
23. Kong L, Dunn GD, Keefer LK, Korthuis RJ. Nitric oxide reduces tumor cell adhesion to isolated rat postcapillary venules. Clin Exp Metastasis 1996, 14:335-343. 10.1007/BF00123392, 8878407.
24. Yamamoto T, Terada N, Seiyama A, Nishizawa Y, Akedo H, Kosaka H. Increase in experimental pulmonary metastasis in mice by L-arginine under inhibition of nitric oxide production by NG-nitro-L-arginine methyl ester. Int J Cancer 1998, 75:140-144. 10.1002/(SICI)1097-0215(19980105)75:1<140::AID-IJC21>3.0.CO;2-J, 9426702.
25. Qiu H, Orr FW, Jensen D, Wang HH, McIntosh AR, Hasinoff BB, Nance DM, Pylypas S, Qi K, Song C, Muschel RJ, Al-Mehdi AB. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am J Pathol 2003, 162:403-412. 1851169, 12547699.
26. Wang HH, McIntosh AR, Hasinoff BB, Rector ES, Ahmed N, Nance DM, Orr FW. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res 2000, 60:5862-5869.
27. Mortensen K, Holck S, Christensen IJ, Skouv J, Hougaard DM, Blom J, Larsson LI. Endothelial cell nitric oxide synthase in peritumoral microvessels is a favorable prognostic indicator in premenopausal breast cancer patients. Clin Cancer Res 1999, 5:1093-1097.
28. Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006, 24:688-694. 10.1200/JCO.2005.04.0436, 16446342.
29. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
30. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551. 10.1200/JCO.2007.15.0375, 18506025.
31. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nikiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388. 10.1056/NEJMoa0909530, 20573926.
32. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128. 10.1016/S1470-2045(09)70364-X, 20022809.